Clinical Trials
585
88 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1948
Active, not recruiting
53
9.1%
Completed
258
44.1%
Enrolling By Invitation
2
0.3%
Not yet recruiting
33
5.6%
Recruiting
112
19.1%
Suspended
3
0.5%
Terminated
32
5.5%
Unknown
78
13.3%
Withdrawn
14
2.4%
No approval data available
- A population-based study of 55,606 Ontario patients found female TBI patients were 26% less likely to be admitted to specialized trauma centres than males, even after adjusting for age, injury severity, and comorbidities. - Female patients were older (median age 78 vs. 67), more often injured by low-energy falls, and had lower rates of severe head trauma (25% vs. 33%) compared to males. - Researchers suggest unconscious sex-related bias and lower prehospital priority for low-energy mechanisms may contribute to the disparity in triage and admission. - The authors call for further investigation into sex- and gender-based variability in trauma triage to guide targeted interventions and reduce disparities.
- Sunnybrook Health Sciences Centre received a $41 million donation from Canada's Weston family to expand clinical trial infrastructure and establish an improved framework for clinical trial research. - The funding will support technical infrastructure including precision diagnostics, biobanking and data management, along with three new leadership positions to oversee research protocols. - The investment aims to integrate clinical trials into standard patient care, reducing the time from discovery to patient impact and positioning Canada as a global leader in clinical trials. - Sunnybrook has previously conducted Canada-first trials in areas including ultrasound technology, cancer, critical care, and brain barrier research using microbubble-enhanced ultrasound.
- Sunnybrook scientists made history by non-invasively opening the blood-brain barrier to deliver immunotherapy directly to the brain of an ALS patient using focused ultrasound technology. - The innovative Next Generation Dome Helmet developed at Sunnybrook allows for targeted drug delivery to brain regions affected by ALS, potentially overcoming a major obstacle in treating neurodegenerative diseases. - This world-first clinical trial will include six participants to test safety and efficacy, potentially revolutionizing treatment approaches for ALS and other neurological conditions where drug delivery is limited by the blood-brain barrier.
- A novel radiopharmaceutical developed by Stephanie Borlase will be used in a clinical trial to track immunotherapy delivery to brain metastases in lung cancer patients. - The trial aims to assess whether ultrasound can disrupt the blood-brain barrier, enhancing the uptake of immunotherapy drugs in brain tumors. - Borlase's radiopharmaceutical combines pembrolizumab (Keytruda) with a radioactive isotope, enabling PET imaging of drug delivery to tumors. - The research offers Borlase a unique opportunity to see her work translated into clinical application, potentially improving outcomes for patients with hard-to-treat cancers.
- The HeLiX randomized clinical trial investigates tranexamic acid's efficacy in reducing blood loss during liver resection, a procedure often associated with significant bleeding. - Paul J. Karanicolas, MD, PhD, FRCSC, presented the trial's design and objectives, focusing on minimizing transfusion requirements and improving patient outcomes. - The study aims to determine if tranexamic acid can effectively decrease the need for blood transfusions and other complications in patients undergoing liver surgery. - Findings from the HeLiX trial could influence clinical guidelines for managing blood loss during liver resections, potentially enhancing surgical safety.
- Health Canada has approved vorasidenib (Voranigo) as the first targeted therapy for Grade 2 IDH-mutant glioma in adults and pediatric patients aged 12 and older, post-surgery. - Clinical trials demonstrated that vorasidenib significantly slowed tumor growth, with a median progression-free survival more than doubled compared to the placebo group (27.7 months vs. 11.1 months). - Vorasidenib is an oral medication designed to cross the blood-brain barrier, targeting mutated enzymes to stabilize or shrink tumors, offering a new treatment option where limited advances have been made in 20 years. - A Toronto firefighter, Steven Stefanidis, who participated in the clinical trials, experienced stabilization and some shrinkage of his tumor with no side effects, and has returned to work.
• A prospective trial evaluated ultrahypofractionated radiotherapy (SBRT) post-prostatectomy for localized prostate cancer, showing it is well-tolerated by patients. • The study reported no grade ≥3 acute genitourinary or gastrointestinal toxicities, suggesting a favorable acute safety profile for the treatment approach. • Health-related quality of life impact was minimal in the acute phase, though longer follow-up is needed to assess long-term toxicity and efficacy. • A multicenter study with a larger cohort has completed enrollment to further validate the safety and efficacy of this radiotherapy modality.
- Sunnybrook researchers have demonstrated the safety of using focused ultrasound to temporarily open the blood-brain barrier in ALS patients, marking a world-first clinical achievement published in Nature Communications. - The groundbreaking technique successfully targeted the motor cortex—a brain region critically affected by ALS—potentially creating a non-invasive pathway for delivering therapeutics directly to affected neural tissues. - Following these promising Phase I results, researchers are preparing to advance to Phase II trials that will involve the delivery of actual ALS therapeutics through the temporarily opened blood-brain barrier.
